Insider · CIK 0001577014
Jason P Rhodes
director
Files at DYN (Dyne Therapeutics, Inc.). First filing Nov 18, 2024, latest Jun 30, 2026.
Jason P Rhodes files SEC Form 4 as director at DYN (Dyne Therapeutics, Inc.). Since Nov 18, 2024, Jason P Rhodes has reported 0 open-market buys worth $0 and 7 open-market sells worth $46M, the latest filed on Jun 30, 2026.
A track record needs three past buys with six months of prices behind them; Jason P Rhodes has 0, so none is measured yet.
The newest scored trade: sold $11M of DYN on Jun 26, 2026, filed Jun 30, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $46M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $46M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DYN: Dyne Therapeutics, Inc.
DYNOct 9, 2026 · close 16.64
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Dyne Therapeutics, Inc. | $11M 504,695 shares | -11% | +156% from low-14% from high | |
| 35Weak | Dyne Therapeutics, Inc. | $5.6M 267,760 shares | -5% | +148% from low-17% from high | |
| 35Weak | Dyne Therapeutics, Inc. | $1.9M 106,723 shares | -7% | +117% from low-27% from high | |
| 33Weak | Dyne Therapeutics, Inc. | $4.2M 227,337 shares | -14% | +122% from low-25% from high | |
| 33Weak | Dyne Therapeutics, Inc. | $7.1M 384,549 shares | -22% | +131% from low-22% from high | |
| 38Weak | Dyne Therapeutics, Inc. | $16M 834,302 shares | -43% | +145% from low-18% from high | |
| 35Weak | Dyne Therapeutics, Inc. | $26k 782 shares | -0% | - |
Transactions
The newest 50 of 80 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -162,954 | $21.28 | $3.5M | 4,579,456 | Jun 30, 2026 |
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -81,903 | $21.28 | $1.7M | 1,396,475 | Jun 30, 2026 |
| Jun 26, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -64,411 | $21.28 | $1.4M | 1,016,633 | Jun 30, 2026 |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -102,969 | $21.14 | $2.2M | 4,476,487 | Jun 30, 2026 |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -51,756 | $21.14 | $1.1M | 1,344,719 | Jun 30, 2026 |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -40,702 | $21.14 | $860k | 975,931 | Jun 30, 2026 |
| Jun 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -77,855 | $21.13 | $1.6M | 4,805,639 | Jun 26, 2026 |
| Jun 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -39,131 | $21.13 | $827k | 1,510,157 | Jun 26, 2026 |
| Jun 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -30,774 | $21.13 | $650k | 1,106,036 | Jun 26, 2026 |
| Jun 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -50,530 | $21.02 | $1.1M | 4,755,109 | Jun 26, 2026 |
| Jun 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -25,397 | $21.02 | $534k | 1,484,760 | Jun 26, 2026 |
| Jun 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,973 | $21.02 | $420k | 1,086,063 | Jun 26, 2026 |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,699 | $21.10 | $268k | 4,742,410 | Jun 26, 2026 |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,382 | $21.10 | $135k | 1,478,378 | Jun 26, 2026 |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,019 | $21.10 | $106k | 1,081,044 | Jun 26, 2026 |
| Jun 5, 2026 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +35,152 | $0.00 | $0 | 35,152 | Jun 9, 2026 |
| May 4, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,136 | $18.00 | $56k | 1,574,270 | May 6, 2026 |
| May 4, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,241 | $18.00 | $112k | 4,933,196 | May 6, 2026 |
| May 4, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -61 | $18.00 | $1,098 | 8,450 | May 6, 2026 |
| May 4, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,466 | $18.00 | $44k | 1,156,457 | May 6, 2026 |
| May 5, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,056 | $18.03 | $55k | 1,571,214 | May 6, 2026 |
| May 5, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,081 | $18.03 | $110k | 4,927,115 | May 6, 2026 |
| May 5, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -60 | $18.03 | $1,082 | 8,390 | May 6, 2026 |
| May 5, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,403 | $18.03 | $43k | 1,154,054 | May 6, 2026 |
| May 6, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -21,926 | $18.18 | $399k | 1,549,288 | May 6, 2026 |
| May 6, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -43,621 | $18.18 | $793k | 4,883,494 | May 6, 2026 |
| May 6, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -428 | $18.18 | $7,781 | 7,962 | May 6, 2026 |
| May 6, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -17,244 | $18.18 | $313k | 1,136,810 | May 6, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -59,870 | $18.38 | $1.1M | 1,577,432 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -119,115 | $18.38 | $2.2M | 4,939,489 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,170 | $18.38 | $22k | 8,512 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -47,082 | $18.38 | $865k | 1,158,944 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -26 | $19.00 | $494 | 1,577,406 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -52 | $19.00 | $988 | 4,939,437 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1 | $19.00 | $19 | 8,511 | Apr 30, 2026 |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -21 | $19.00 | $399 | 1,158,923 | Apr 30, 2026 |
| Apr 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,261 | $19.19 | $370k | 1,719,356 | Apr 27, 2026 |
| Apr 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -38,322 | $19.19 | $735k | 5,221,857 | Apr 27, 2026 |
| Apr 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -377 | $19.19 | $7,235 | 11,286 | Apr 27, 2026 |
| Apr 23, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -15,148 | $19.19 | $291k | 1,270,556 | Apr 27, 2026 |
| Apr 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -36,345 | $18.48 | $672k | 1,683,011 | Apr 27, 2026 |
| Apr 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -72,310 | $18.48 | $1.3M | 5,149,547 | Apr 27, 2026 |
| Apr 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -710 | $18.48 | $13k | 10,576 | Apr 27, 2026 |
| Apr 24, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -28,583 | $18.48 | $528k | 1,241,973 | Apr 27, 2026 |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -45,709 | $18.15 | $830k | 1,637,302 | Apr 27, 2026 |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -90,943 | $18.15 | $1.7M | 5,058,604 | Apr 27, 2026 |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -894 | $18.15 | $16k | 9,682 | Apr 27, 2026 |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -35,947 | $18.15 | $652k | 1,206,026 | Apr 27, 2026 |
| Apr 20, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -71,676 | $20.06 | $1.4M | 1,886,751 | Apr 22, 2026 |
| Apr 20, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -142,604 | $20.06 | $2.9M | 5,554,904 | Apr 22, 2026 |
50 of 80 rows shown.
Questions about Jason P Rhodes
Answered from the filings on this page, as of the latest one.
Is Jason P Rhodes buying or selling?
In the last 12 months Jason P Rhodes reported 0 open-market buys worth $0 and 6 open-market sells worth $46M on SEC Form 4; the latest was sold $11M of DYN on Jun 26, 2026. Grants, option exercises and tax withholding are not counted.
How did Jason P Rhodes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jason P Rhodes has 0.
Where does Jason P Rhodes file Form 4?
Jason P Rhodes has filed Form 4 at DYN (Dyne Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.